Top Analysts Highlight Biotech and Crypto-Associated Stocks as Strong Buys

Wall Street's top analysts have identified Gossamer Bio (GOSS) and DeFi Technologies (DEFT) as standout investment opportunities. Gossamer, a California-based biotech firm specializing in immune and inflammatory therapies, received unanimous Buy ratings from six analysts with a projected 260% upside. Oppenheimer's Andreas Argyrides maintained a $9 price target, citing the company's pipeline in oncology and immunology.

DeFi Technologies, a digital asset manager with $700M AUM, drew attention for its crypto-linked exchange-traded products. While the analyst firm wasn't named, the mention of H.C. Wainwright suggests institutional interest in vehicles bridging traditional finance with decentralized assets. The crypto exposure aligns with growing demand for regulated entry points into blockchain markets.